# A Study to Investigate the Safety, Tolerability, PK and PD of MG1113 in Healthy Subjects and Hemophilia Patients

> **NCT03855696** · PHASE1 · COMPLETED · sponsor: **Green Cross Corporation** · enrollment: 41 (actual)

## Conditions studied

- Hemophilia

## Interventions

- **BIOLOGICAL:** MG1113
- **OTHER:** Placebo of MG1113

## Key facts

- **NCT ID:** NCT03855696
- **Lead sponsor:** Green Cross Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-21
- **Primary completion:** 2021-06-30
- **Final completion:** 2021-08-31
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2021-10-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03855696

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03855696, "A Study to Investigate the Safety, Tolerability, PK and PD of MG1113 in Healthy Subjects and Hemophilia Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03855696. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*